- Previous Close
51.48 - Open
51.50 - Bid 51.59 x 100
- Ask 51.83 x 100
- Day's Range
51.03 - 51.96 - 52 Week Range
42.75 - 64.47 - Volume
171,704 - Avg. Volume
668,196 - Market Cap (intraday)
2.807B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.31 - Earnings Date Oct 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
71.89
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
www.livanova.comRecent News: LIVN
View More
Performance Overview: LIVN
Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIVN
View MoreValuation Measures
Market Cap
2.79B
Enterprise Value
3.14B
Trailing P/E
--
Forward P/E
21.14
PEG Ratio (5yr expected)
0.47
Price/Sales (ttm)
2.31
Price/Book (mrq)
2.25
Enterprise Value/Revenue
2.60
Enterprise Value/EBITDA
329.10
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.37%
Return on Assets (ttm)
3.34%
Return on Equity (ttm)
-1.34%
Revenue (ttm)
1.21B
Net Income Avi to Common (ttm)
-16.59M
Diluted EPS (ttm)
-0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
329.24M
Total Debt/Equity (mrq)
54.53%
Levered Free Cash Flow (ttm)
132.39M
Research Analysis: LIVN
View MoreCompany Insights: LIVN
LIVN does not have Company Insights
Research Reports: LIVN
View MoreRating decreased to a SELL
LIVANOVA PLC has an Investment Rating of SELL; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLivaNova Narrows Its Focus to Cardiopulmonary and Neuromodulation
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
RatingPrice TargetLowering target price to $49.00
LIVANOVA PLC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLivaNova Earnings: Strong Execution and New Product Cycle Support Outperformance
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
RatingPrice Target